View in EDS PDF Full Text

Comparación de la calidad de vida entre los pacientes con psoriasis tratados con inhibidores del factor de necrosis tumoral (TNF) y metotrexato.

Saved in:
Bibliographic Details
Title: Comparación de la calidad de vida entre los pacientes con psoriasis tratados con inhibidores del factor de necrosis tumoral (TNF) y metotrexato.
Alternate Title: Comparison of quality of life among patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors and methotrexate.
Authors: Aparicio Sánchez, Elisa Estefanía1 elisaaparicio2@gmail.com, Díaz Fernández, Mónica2, Ledesma De la Torre, Claudia2, Rodríguez Nieto, María de Lourdes2, Ordoñez Rodríguez, Tatiana3
Source: Dermatología Revista Mexicana. ene/feb2026, Vol. 70 Issue 1, p13-19. 7p.
Subjects: QUALITY of life, METHOTREXATE, PSORIASIS, ETANERCEPT, ADALIMUMAB, TUMOR necrosis factors, QUALITY of life measurement
Abstract (English): OBJECTIVE: To determine if there is a significant difference between the Dermatological Life Quality Index (DLQI) of patients with a diagnosis of psoriasis treated with etanercept, adalimumab and methotrexate. MATERIALS AND METHODS: Observational, comparative, descriptive and cross-sectional study, performed from November 1st, 2022 to January 1st, 2023. The DLQI score was compared in patients older than 18 years of age with a diagnosis of psoriasis treated with adalimumab, etanercept, and methotrexate. Data distribution and comparison between groups were performed with the Shapiro-Wilk and Mann-Whitney U tests. A value of p < 0.05 was considered a statistically significant difference. RESULTS: A representative sample of 34 patients was taken and distributed into three main groups according to the treatment administered: etanercept (n = 7), adalimumab (n = 18), and methotrexate (n = 9). The DLQI score obtained in the three groups studied was: etanercept (median = 3 points), adalimumab (median = 1 point), and methotrexate (median = 3 points). The results showed a significantly lower DLQI score in patients treated with adalimumab compared to etanercept. No statistically significant differences were found between the scores of methotrexate and both biologicals. CONCLUSIONS: Among biological drugs, patients treated with adalimumab achieve lower DLQI scores; however, etanercept and adalimumab did not prove to be superior to methotrexate in improving quality of life. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): OBJETIVO: Determinar si existe diferencia significativa entre el puntaje del Índice de Calidad de Vida Dermatológica (DLQI) de pacientes con diagnóstico de psoriasis tratados con etanercept, adalimumab y metotrexato. MATERIALES Y MÉTODOS: Estudio observacional, comparativo, descriptivo y transversal, efectuado del 1 de noviembre de 2022 al 1 de enero de 2023, en el que se comparó el puntaje de DLQI en pacientes de 18 años o más con diagnóstico de psoriasis en tratamiento con adalimumab, etanercept y metotrexato. La distribución de los datos y la comparación entre grupos se hizo con las pruebas de Shapiro-Wilk y U de Mann-Whitney. Un valor de p menor de 0.05 se consideró diferencia estadísticamente significativa. RESULTADOS: Se tomó una muestra representativa de 34 pacientes que se distribuyeron en tres grupos principales según el tratamiento administrado: etanercept (n = 7), adalimumab (n = 18) y metrotexato (n = 9). El puntaje obtenido de DLQI en los tres grupos estudiados fue: etanercept (mediana = 3 puntos), adalimumab (mediana = 1 punto) y metotrexato (mediana = 3 puntos). Los resultados mostraron un puntaje de DLQI significativamente menor en los pacientes tratados con adalimumab en comparación con etanercept. No se hallaron diferencias estadísticamente significativas entre los puntajes de metotrexato y ambos biológicos. CONCLUSIONES: Entre fármacos biológicos, los pacientes tratados con adalimumab alcanzaron puntajes de DLQI más bajos; sin embargo, etanercept y adalimumab no demostraron ser superiores al metotrexato en la mejoría de la calidad de vida. [ABSTRACT FROM AUTHOR]
Copyright of Dermatología Revista Mexicana is the property of Edicion y Farmacia S.A. de C.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Description
Abstract:OBJECTIVE: To determine if there is a significant difference between the Dermatological Life Quality Index (DLQI) of patients with a diagnosis of psoriasis treated with etanercept, adalimumab and methotrexate. MATERIALS AND METHODS: Observational, comparative, descriptive and cross-sectional study, performed from November 1st, 2022 to January 1st, 2023. The DLQI score was compared in patients older than 18 years of age with a diagnosis of psoriasis treated with adalimumab, etanercept, and methotrexate. Data distribution and comparison between groups were performed with the Shapiro-Wilk and Mann-Whitney U tests. A value of p < 0.05 was considered a statistically significant difference. RESULTS: A representative sample of 34 patients was taken and distributed into three main groups according to the treatment administered: etanercept (n = 7), adalimumab (n = 18), and methotrexate (n = 9). The DLQI score obtained in the three groups studied was: etanercept (median = 3 points), adalimumab (median = 1 point), and methotrexate (median = 3 points). The results showed a significantly lower DLQI score in patients treated with adalimumab compared to etanercept. No statistically significant differences were found between the scores of methotrexate and both biologicals. CONCLUSIONS: Among biological drugs, patients treated with adalimumab achieve lower DLQI scores; however, etanercept and adalimumab did not prove to be superior to methotrexate in improving quality of life. [ABSTRACT FROM AUTHOR]
ISSN:01854038
DOI:10.24245/dermatolrevmex.v70i1.10945